- World rank, all time
- #40,802 of 42,892
- Rank in France
- #2,162 of 2,321
- Research works
- 141 ▲ 204% vs 2013–17
- Citations
- 710 5.0 per fractional work
- Top-10% rate
- 10.3% record average 16.5%
- Open access
- 40% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.7×. Every wedge is a field page.
- Medicine 3.7×
- Immunology and Microbiology 3.1×
- Pharmacology, Toxicology and Pharmaceutics 2.7×
- Veterinary 2.7×
- Health Professions 2.3×
- Nursing 1.9×
- Dentistry 1.1×
- Biochemistry, Genetics and Molecular Biology 1.0×
- Neuroscience 0.9×
- Psychology 0.4×
- Economics, Econometrics and Finance 0.4×
- Computer Science 0.3×
- Decision Sciences 0.3×
- Social Sciences 0.3×
- Materials Science 0.1×
- Arts and Humanities 0.1×
- Chemistry 0.1×
- Mathematics 0.1×
- Agricultural and Biological Sciences 0.1×
- Environmental Science 0.0×
- Engineering 0.0×
Who are the top researchers at Groupe Hospitalier de la Région de Mulhouse et Sud Alsace?
Ranked on the composite score, D. Debieuvre lead among researchers whose main affiliation is Groupe Hospitalier de la Région de Mulhouse et Sud Alsace.
- 1 D. Debieuvre France · #327,748 worldwide 172 citations · 79 works
Which keywords describe research at Groupe Hospitalier de la Région de Mulhouse et Sud Alsace?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Epidemiology, Targeted Therapy, Clinical Trials, Prognostic Factors, Management, Cultural Heritage and Treatment Guidelines.
- Small-Cell Lung Cancer
- Law
- Genomic Profiles
- Therapeutic Targets
- Genetics
- CT Screening
- Treatment
- Immune Response
- Patient Rights
- Adjuvant Therapy
- Radiotherapy
- Metastasis
- Biomarkers
- Genomic Profiling
- ALK Inhibitors
- Mental Health
- Diagnosis
- Inflammation
- Clinical Trials
- Chemotherapy
- Epidemiology
- Targeted Therapy
- Prognostic Factors
- Management
- Cultural Heritage
- Risk Factors
- EGFR Mutations
- Treatment Guidelines
- Immunotherapy
- Palliative Care
- Thrombosis
- Healthcare Legislation
- Rituximab
- Lung Cancer
- Tumor Staging
- Genetic Mutations
- Positron Emission Tomography
- Digital Communication
- Information Studies
- Linguistics
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology5▲ 2.9×42 topics
- Chemotherapy4▲ 11×15 topics
- Targeted Therapy3▲ 31×4 topics
- Clinical Trials3▲ 9.9×4 topics
- Prognostic Factors3▲ 15×8 topics
- Inflammation2▲ 2.6×23 topics
- Management2▲ 6.7×14 topics
- Diagnosis2▲ 5.3×18 topics
- Cultural Heritage2▲ 8.0×2 topics
- Mental Health2▲ 3.0×6 topics
- Risk Factors2▲ 3.9×7 topics
- ALK Inhibitors2▲ 67×1 topic
- EGFR Mutations2▲ 67×1 topic
- Genomic Profiling2▲ 41×2 topics
- Treatment Guidelines2▲ 20×3 topics
- Biomarkers2▲ 5.3×7 topics
- Immunotherapy2▲ 5.3×13 topics
- Metastasis2▲ 11×7 topics
- Palliative Care2▲ 23×3 topics
- Radiotherapy2▲ 9.5×7 topics
- Thrombosis2▲ 14×7 topics
- Adjuvant Therapy2▲ 28×2 topics
- Healthcare Legislation2▲ 59×1 topic
- Patient Rights2▲ 48×1 topic
- Rituximab2▲ 23×3 topics
- Immune Response1▲ 4.5×6 topics
- Lung Cancer1▲ 15×3 topics
- Treatment1▲ 2.2×13 topics
- Tumor Staging1▲ 24×2 topics
- CT Screening1▲ 36×1 topic
- Genetic Mutations1▲ 5.5×10 topics
- Genetics1▲ 3.5×6 topics
- Positron Emission Tomography1▲ 36×1 topic
- Therapeutic Targets1▲ 15×4 topics
- Digital Communication1▲ 31×1 topic
- Genomic Profiles1▲ 54×1 topic
- Information Studies1▲ 104×1 topic
- Law1▲ 159×1 topic
- Linguistics1▲ 13×1 topic
- Small-Cell Lung Cancer1▲ 54×1 topic
Which research topics does Groupe Hospitalier de la Région de Mulhouse et Sud Alsace publish most on?
By volume in 2022–2025: Lung Cancer Treatments and Mutations, Health, Medicine and Society, Lung Cancer Diagnosis and Treatment and Hume's philosophy and hair distribution.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 2 Health, Medicine and Society General Health Professions 2 works
- 3 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
- 4 Hume's philosophy and hair distribution General Social Sciences 1 works
- 5 Lung Cancer Research Studies Oncology 1 works
- 6 Cultural Insights and Digital Impacts Computer Networks and Communications 1 works
- 7 Chronic Lymphocytic Leukemia Research Genetics 1 works
- 8 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 9 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 1 works
- 10 Respiratory Support and Mechanisms Pulmonary and Respiratory Medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Groupe Hospitalier de la Région de Mulhouse et Sud Alsace's research output changed?
Output in 2018–2022 was 204% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Mulhouse
- Université de Haute-Alsace
- Laboratoire de Photochimie et d'Ingénierie Macromoléculaire
- Institut de Sciences des Matériaux de Mulhouse
- Centre Hospitalier de Mulhouse
- Institut de Recherche en Hématologie et Transplantation
- Hôpital du Hasenrain
- Rhenovia (France)
- Institut de Prise en Charge de l'Obésité en Alsace
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.